Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors

PPublication Type:

Article

Authors:

Sophie C. Cazanave, Andrew D. Warren , Maciej Pacula , Fayçal Touti , Anna Zagorska, Nil Gural, Eric K. Huang , Sarah Sherman, Mehar Cheema , Sabrina Ibarra , Jamie Bates, Andrew N. Billin, John T. Liles, Grant R. Budas, David G. Breckenridge , Dina Tiniakos, Vlad Ratziu, Ann K. Daly, Olivier Govaere , Quentin M. Anstee, Louis Gelrud, Jay Luther, Raymond T. Chung, Kathleen E. Corey , Wendy Winckler, Sangeeta Bhatia, Gabriel A. Kwong

Source:

Science Translational Medicine (2021)

URL:

https://www.science.org/doi/10.1126/scitranslmed.abe8939

Abstract:

Noninvasive detection of nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease, promises to improve patient screening, accelerate drug trials, and reduce health care costs. On the basis of protease dysregulation of the biological pathways of fibrotic NASH, we developed the Glympse Bio Test System (GBTS) for multiplexed quantification of liver protease activity. GBTS-NASH comprises a mixture of 19 mass-barcoded PEGylated peptides that is administered intravenously and senses liver protease activity by releasing mass-barcoded reporters into urine for analysis by mass spectrometry. To identify a protease signature of NASH, transcriptomic analysis of 355 human liver biopsies identified a 13-protease panel that discriminated clinically relevant NASH ≥F2 fibrosis from F0-F1 with high classification accuracy across two independent patient datasets. We screened 159 candidate substrates to identify a panel of 19 peptides that exhibited high activity for our 13-protease panel. In the choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) mouse model, binary classifiers trained on urine samples discriminated fibrotic NASH from simple steatosis and healthy controls across a range of nondisease conditions and indicated disease regression upon diet change [area under receiver operating characteristics (AUROCs) > 0.97]. Using a hepatoprotective triple combination treatment (FXR agonist, ACC and ASK1 inhibitors) in a rat model of NASH, urinary classification distinguished F0-F1 from ≥F2 animals and indicated therapeutic response as early as 1 week on treatment (AUROCs >0.91). Our results support GBTS-NASH to diagnose fibrotic NASH via an infusion of peptides, monitor changes in disease severity, and indicate early treatment response.

Manuscript (PDF)

Supporting information (PDF)